Compare MURA & LGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MURA | LGL |
|---|---|---|
| Founded | 2013 | 1917 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Machinery/Components |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 34.1M |
| IPO Year | N/A | N/A |
| Metric | MURA | LGL |
|---|---|---|
| Price | $2.03 | $5.68 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 224.8K | 8.7K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 149.85 |
| EPS | N/A | ★ 0.17 |
| Revenue | N/A | ★ $4,107,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $33.79 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.95 | $5.45 |
| 52 Week High | $4.74 | $9.74 |
| Indicator | MURA | LGL |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 43.01 |
| Support Level | $2.06 | $5.62 |
| Resistance Level | $2.10 | $5.99 |
| Average True Range (ATR) | 0.01 | 0.27 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 25.00 | 31.03 |
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.